Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR4 | O00206 | 2/20 | 0.64 |
| ▸ | TLR2 | O60603 | 2/20 | 0.64 |
| ▸ | MAOA | P21397 | 7/20 | 0.50 |
| ▸ | MAOB | P27338 | 7/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.47 |
| ▸ | SRC | P12931 | 1/20 | 0.45 |
| ▸ | GRM5 | P41594 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29612417 | 0.82 | TLR4 (0.56) | TLR4TLR2ALDH1A1POLBFFAR4 | |
| SCHEMBL12129555 | 0.82 | TLR4 (0.56) | TLR4TLR2ALDH1A1POLBFFAR4 | |
| SCHEMBL3933029 | 0.81 | ALDH1A1 (0.66) | TLR4TLR2MAOAMAOBALDH1A1 | |
| SCHEMBL31238491 | 0.81 | ALDH1A1 (0.66) | TLR4TLR2ALDH1A1POLBL3MBTL1 | |
| SCHEMBL510396 | 0.81 | ALDH1A1 (0.66) | TLR4TLR2ALDH1A1POLBL3MBTL1 | |
| SCHEMBL25401405 | 0.81 | TLR4 (0.58) | TLR4TLR2ALDH1A1L3MBTL1FFAR4 | |
| SCHEMBL15602369 | 0.81 | TLR4 (0.55) | TLR4TLR2ALDH1A1FFAR4GRM5 | |
| SCHEMBL10544371 | 0.80 | TLR4 (0.56) | TLR4TLR2ALDH1A1POLBL3MBTL1 | |
| SCHEMBL10545780 | 0.80 | TLR4 (0.56) | TLR4TLR2ALDH1A1POLBL3MBTL1 | |
| SCHEMBL18131575 | 0.79 | TLR4 (1.00) | TLR4TLR2MAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12570675-B2 | Boronic acid compounds | LG CHEM, LTD. (KR) | 2026-03-10 | — | — | US | disclosed |
| US-20240101579-A1 | BORONIC ACID COMPOUNDS | LG CHEM, LTD. (KR) | 2024-03-28 | — | — | US | disclosed |
| EP-4242213-A1 | BORONIC ACID COMPOUND | Lg Chem, Ltd. (KR) | 2023-09-13 | — | — | EP | disclosed |
| CN-116568310-A | Boric acid compounds | 株式会社LG化学 | 2023-08-08 | — | — | CN | disclosed |
| WO-2022123530-A1 | BORONIC ACID COMPOUND | 주식회사 엘지화학 | 2022-06-16 | — | — | WO | disclosed |
| WO-2022123530-A1 | BORONIC ACID COMPOUND | 주식회사 엘지화학 | 2022-06-16 | — | — | WO | disclosed |
| CN-107466290-B | Substituted cyclic amides as herbicides | FMC公司 | 2021-08-03 | — | — | CN | disclosed |
| EP-3280709-B1 | SUBSTITUTED CYCLIC AMIDES AS HERBICIDES | FMC CORP (US) | 2021-05-26 | — | — | EP | disclosed |
| US-10405547-B2 | Substituted cyclic amides as herbicides | FMC CORPORATION (US) | 2019-09-10 | — | — | US | disclosed |
| US-10377745-B2 | Heterocyclic compounds as NaV channel inhibitors and uses thereof | MERCK PATENT GMBH (DE) | 2019-08-13 | — | — | US | disclosed |
| EP-1688138-A1 | RECEPTOR FUNCTION REGULATING AGENT | Takeda Pharmaceutical Company Limited (JP) | 2006-08-09 | — | — | EP | disclosed |
| US-20060009511-A9 | N-(2-arylethyl) benzylamines as antagonists of the 5-ht6 receptor | CHEN ZHAOGEN | 2006-01-12 | — | — | US | disclosed |
| EP-1583759-A1 | PYRIDINE DERIVATIVES USEFUL FOR INHIBITING SODIUM/CALCIUM EXCHANGE SYSTEM | ORION CORPORATION (FI) | 2005-10-12 | — | — | EP | disclosed |
| WO-2004063191-A1 | PYRIDINE DERIVATIVES USEFUL FOR INHIBITING SODIUM/CALCIUM EXCHANGE SYSTEM | ORION CORPORATION (FI) | 2004-07-29 | — | — | WO | disclosed |
| EP-1379239-A2 | N-(2-ARYLETHYL) BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR | ELI LILLY AND COMPANY (US) | 2004-01-14 | — | — | EP | disclosed |
| WO-2002078693-A2 | N-(2-ARYLETHYL)BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR | ELI LILLY AND COMPANY (US) | 2002-10-10 | — | — | WO | disclosed |
| EP-0436199-B1 | Cyclopropyl derivative lipoxygenase inhibitors | ABBOTT LAB (US) | 1994-08-03 | — | — | EP | disclosed |
| US-5120752-A | N-(1-(20(3-pyridyloxy)phenyl)cyclopropyl) alkyl-N-hydroxyurea compounds, antiinflammatory agents | ABBOTT LABORATORIES (US) | 1992-06-09 | — | — | US | disclosed |
| US-5037853-A | Antiinflammatory agents | ABBOTT LABORATORIES (US) | 1991-08-06 | — | — | US | disclosed |
| EP-0436199-A1 | Cyclopropyl derivative lipoxygenase inhibitors | ABBOTT LABORATORIES (US) | 1991-07-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12570675-B2 | Boronic acid compounds | PSMB6, PSMB3, PSMB2 | TLR4 2938/4885TLR2 1648/4885MAOA 2010/4885 |
| US-20060009511-A9 | N-(2-arylethyl) benzylamines as antagonists of the 5-ht6 receptor | HTR6, HTR2C, HTR1B | TLR4 2004/4885TLR2 942/4885MAOA 75/4885 |
| US-20240101579-A1 | BORONIC ACID COMPOUNDS | PSMB11, PSMB1, BACH1 | TLR4 2289/4885TLR2 1904/4885MAOA 2844/4885 |
| US-10405547-B2 | Substituted cyclic amides as herbicides | CYP1A1, CYP1B1, QSOX1 | TLR4 3620/4885TLR2 2454/4885MAOA 825/4885 |
| US-10377745-B2 | Heterocyclic compounds as NaV channel inhibitors and uses thereof | CACNA1B, CACNG6, SCN5A | TLR4 3399/4885TLR2 4423/4885MAOA 2038/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.